Current Report Filing (8-k)
December 19 2017 - 3:56PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 14
th
, 2017
CANNABICS PHARMACEUTICALS INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
000-52403
|
20-3373669
|
(State of incorporation)
|
(Commission File Number)
|
(IRS Employer No.)
|
#3 Bethesda Metro Center
Suite 700
Bethesda, Md 20814
(Address of principal executive offices
and Zip Code)
877 424-2429
(Registrant's telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 1.01
|
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
|
On December 14
th
,
2017, GRIN Ultra Ltd., the R&D subsidiary of Cannabics Pharmaceuticals Inc., (“the Company”) executed a Sales,
Support & Maintenance Agreement with Rhenium Equipment for Research Labs Ltd., a premier Israeli Research & Diagnostic
equipment supplier for acquisition of custom designed and fully automated CTC (Circulating Tumor Cells) and HTS (High Through
Output Screening) machines, including a service agreement for the next two years to service said equipment. The total cost of
said agreement was $747,689.00, which was paid in full to Rhenium.
With the execution
of this Agreement, the Company is now exploiting its acquired and patented knowledge relating to genomic data, cancer detection
and screening by installing this cutting-edge diagnostic equipment in its licensed laboratory in Tel Aviv, Israel.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 19
th
, 2017
|
Cannabics Pharmaceuticals Inc.
|
|
|
|
|
|
|
/s/ Itamar Borochov
|
|
By:
|
Itamar Borochov, Dir., CEO
|
|
|
|
|
|
|
|
By:
|
/s/ Dr. Eyal Ballan
|
|
|
Dr. Eyal Ballan, Dir., CTO
|
|
|
|
|
|
|
|
By:
|
/s/ Eyal Barad
|
|
|
Eyal Barad, Dir., COO
|
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Aug 2024 to Sep 2024
CNBX Pharmaceuticals (QB) (USOTC:CNBX)
Historical Stock Chart
From Sep 2023 to Sep 2024